🇺🇸 FDA
Company

Editas

Editas Medicine

EDIT biotech USA

Quick answer

Editas is a biotech company (EDIT) headquartered in CAMBRIDGE, MA, USA with 3 tracked pipeline programs.

Pipeline (3)

project

EDIT-101

Leber Congenital Amaurosis 10

Phase 2 · small_molecule · active

1 trials project

EDIT-301

Sickle Cell Disease

Phase 2 · gene_therapy · active

1 trials project

EDIT-301

Transfusion Dependent Beta Thalassemia

Phase 2 · gene_therapy · active

1 trials

Patents (8)

patent

US 12359223

Systems and methods for modulating chromosomal rearrangements

Expires Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12331328

CRISPR/Cas9-mediated exon-skipping approach for USH2A-associated usher syndrome

Expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12325854

Crispr-CPF1-related methods, compositions and components for cancer immunotherap

Expires Mon Jun 05 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12201699

Compositions and methods for promoting homology directed repair

Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12031132

Systems and methods for the treatment of hemoglobinopathies

Expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11963982

CRISPR/RNA-guided nuclease systems and methods

Expires Mon Apr 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11952408

HPV-specific binding molecules

Expires Mon Apr 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11911415

CRISPR/Cas-related methods and compositions for improving transplantation

Expires Mon Feb 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)